Intensive blood pressure control cuts dementia risk 15% in rural China trial

Dementia is coming. The numbers are stark enough to reshape how public health systems think about prevention: 57 million people worldwide lived with dementia in 2019, and by 2050 that figure is expected to climb to 153 million. There is no cure. So the question becomes urgent: what can actually be prevented?

A seven-year trial conducted across 326 rural villages in China offers one answer. Researchers found that aggressive management of high blood pressure, delivered by trained community health workers rather than doctors, reduced the risk of dementia by 15 percent. The study enrolled nearly 34,000 people with an average age of 63, about 61 percent of them women. Over the course of four years of active intervention followed by three years of observation, the difference between intensive treatment and standard care became measurable and significant.

The intervention itself was straightforward. Non-physician healthcare providers, working under a simple protocol and supervised by primary-care physicians, prescribed and adjusted blood pressure medications with a specific target: systolic pressure below 130 millimeters of mercury and diastolic below 80. In the usual-care group, patients received standard treatment without this structured approach. By the end of seven years, the intervention group had achieved a systolic blood pressure reduction of 17.6 millimeters of mercury compared to just 2.4 millimeters in the usual-care group. That gap in blood pressure control translated into a gap in dementia incidence: 8.85 percent of the intervention group developed dementia versus 10.55 percent of the usual-care group.

These numbers matter because they come from a population-level trial, not a laboratory study or a small clinical sample. The China Rural Hypertension Control Program, as it is formally known, was led by Professor Yingxian Sun of The First Affiliated Hospital of China Medical University. The results were presented at the European Society of Cardiology Congress in 2026. Hypertension has long been known as a modifiable risk factor for dementia—meaning it can be changed—but until now, there has been limited long-term evidence that actually lowering blood pressure at scale prevents dementia in real communities.

The trial also found that the intervention group had a 13 percent lower risk of cognitive impairment without full dementia, and that serious adverse events were actually less common in the intensive-treatment group than in usual care: 47.15 percent versus 49.78 percent. This last finding is important because it suggests the intervention did not create new harms in pursuit of lower numbers.

What makes this trial particularly relevant for global health systems is its design. The intervention was not delivered by specialists or highly trained physicians. It was delivered by community healthcare providers using a stepped-care protocol—a simple, tiered approach to medication adjustment. This matters because it suggests the approach could be scaled. Rural China faces the same constraint many health systems do: there are not enough doctors to go around. If blood pressure management can be systematized and delegated to trained community workers, the intervention becomes feasible in places where it might otherwise remain out of reach.

Professor Sun concluded that the results support integrating structured blood pressure management into routine primary care as a strategy for preventing dementia at the population level. The implication is clear: as dementia cases are projected to nearly triple globally over the next 25 years, and as no cure exists, the prevention strategies that work need to be identified, tested, and then woven into the fabric of how primary care operates. This trial suggests that one such strategy—careful, systematic blood pressure control delivered by the healthcare workers already embedded in communities—can make a measurable difference.